An Alternate Future

We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.

First-in-class therapies to treat neurodegenerative disease

Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.

Our therapies

Latest News

XBRL 30 June 2023 filed with the SEC

September 1, 2023

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

August 31, 2023

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s

August 23, 2023